Free Trial
NASDAQ:TRVN

Trevena (TRVN) Stock Price, News & Analysis

Trevena logo
$0.01 +0.00 (+7.14%)
As of 09:35 AM Eastern

About Trevena Stock (NASDAQ:TRVN)

Advanced

Key Stats

Today's Range
$0.0120
▼
$0.0120
50-Day Range
N/A
52-Week Range
$0.00
▼
$1.50
Volume
194 shs
Average Volume
751 shs
Market Capitalization
$11.51 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Trevena, Inc. is a biopharmaceutical company focused on developing medicines that target G protein-coupled receptors (GPCRs), a class of proteins involved in pain, neurological conditions and other diseases. The company was founded in 2007 and is headquartered in Chesterbrook, Pennsylvania.

Trevena’s best-known product is OLINVYK (oliceridine) injection, an intravenous opioid analgesic approved by the U.S. Food and Drug Administration in 2020 for the management of acute pain severe enough to require an intravenous opioid analgesic in adults. OLINVYK was designed as a selective mu-opioid receptor agonist and was developed to provide pain relief while addressing certain limitations associated with traditional opioid therapies.

The company has also conducted research on additional therapies for pain and central nervous system disorders, including investigational oral and non-opioid treatments. Trevena’s primary commercial and regulatory activities have been focused on the United States, while its development programs and partnerships have supported efforts to expand the potential reach of its drug candidates. Because the company’s operations and product-development activities have changed over time, investors should consult its latest public filings for current information about its leadership, pipeline and commercial status.

AI Generated. May Contain Errors.

Receive TRVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevena and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TRVN Stock News Headlines

Trevena Inc.
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
Trevena, Inc. (TRVN) - Yahoo Finance
JMP Securities downgrades Trevena (TRVN) to a Hold
See More Headlines

TRVN Stock Analysis - Frequently Asked Questions

Trevena's stock was trading at $0.0120 at the start of the year. Since then, TRVN stock has increased by 0.0% and is now trading at $0.0120.

Trevena, Inc. (NASDAQ:TRVN) released its quarterly earnings data on Thursday, August, 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($9.25) by $9.02. The biopharmaceutical company had revenue of $0.33 million for the quarter.

Trevena shares reverse split on the morning of Tuesday, August 13th 2024.The 1-25 reverse split was announced on Thursday, August 8th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Shares of TRVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Trevena investors own include Novavax (NVAX), Conatus Pharmaceuticals (CNAT), Sorrento Therapeutics (SRNE), NIO (NIO), TherapeuticsMD (TXMD), SCYNEXIS (SCYX).

Company Calendar

Last Earnings
8/08/2024
Today
10/05/2026
Next Earnings (Estimated)
11/05/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:TRVN
CIK
1429560
Fax
N/A
Employees
23
Year Founded
2008

Profitability

EPS (Trailing Twelve Months)
($47.04)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$40.29 million
Net Margins
N/A
Pretax Margin
-6,222.30%
Return on Equity
N/A
Return on Assets
-119.55%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.42
Quick Ratio
2.42

Sales & Book Value

Annual Sales
$443 thousand
Price / Sales
0.03
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($11.07) per share
Price / Book
0.00

Miscellaneous

Outstanding Shares
959,000
Free Float
841,000
Market Cap
$11.51 thousand
Optionable
No Data
Beta
-0.55

Social Links

7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:TRVN) was last updated on 10/5/2026 by MarketBeat.com Staff.
From Our Partners